Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax^®) in children

References

• BauchauVDurhamSPrevalence and rate of diagnosis of allergic rhinitis in EuropeEur Respir J20042475876415516669
   PubMed Web of Science ®Google Scholar
• AsherMIMontefortSBjorkstenBWorldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveysLancet200636873374316935684
   PubMed Web of Science ®Google Scholar
• BousquetJKhaltaevNCruzAAAllergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)Allergy200863Suppl 86816018331513
   PubMed Web of Science ®Google Scholar
• BousquetJVan CauwenbergePKhaltaevNAllergic rhinitis and its impact on asthmaJ Allergy Clin Immunol2001108S147S33411707753
   PubMed Web of Science ®Google Scholar
• LinnebergAHenrik NielsenNFrolundLThe link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy StudyAllergy2002571048105212359002
   PubMed Web of Science ®Google Scholar
• Royal College of PhysiciansAllergy: the unmet need A blueprint for better patient careA report of the Royal College of Physicians Working Party on the provision of allergy services in the UKLondon, UKRoyal College of Physicians2003 Available from: http://www.bsaci.org/pdf/allergy_the_unmet_need.pdfAccessed October 3, 2013
   Google Scholar
• JacobsenLNiggemannBDreborgSSpecific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT studyAllergy20076294394817620073
   PubMed Web of Science ®Google Scholar
• MollerCDreborgSFerdousiHAPollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)The J Allergy Clin Immunol2002109251256
   PubMed Web of Science ®Google Scholar
• NiggemannBJacobsenLDreborgSFive-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in childrenAllergy20066185585916792584
   PubMed Web of Science ®Google Scholar
• BufeAEberlePFranke-BeckmannESafety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapyJ Allergy Clin Immunol2009123167173. e719130937
   PubMed Web of Science ®Google Scholar
• DurhamSRWalkerSMVargaEMLong-term clinical efficacy of grass-pollen immunotherapyN Engl J Med199934146847510441602
   PubMed Web of Science ®Google Scholar
• DahlRKappAColomboGSublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 yearsJ Allergy Clin Immunol2008121512518. e218155284
   PubMed Web of Science ®Google Scholar
• Di RienzoVMarcucciFPuccinelliPLong-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective studyClin Exp Allergy20033320621012580913
   PubMed Web of Science ®Google Scholar
• DurhamSRYangWHPedersenMRSublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitisJ Allergy Clin Immunol200611780280916630937
   PubMed Web of Science ®Google Scholar
• DurhamSRSustained efficacy of the SQ-standardized grass allergy immunotherapy tablet during the peak grass pollen season 2 years after treatmentAllergy2012651875
   Web of Science ®Google Scholar
• BachertCVestenbaekUChristensenJCost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen-induced rhinoconjunctivitis – a Northern European perspectiveClin Exp Allergy20073777277917456225
   PubMed Web of Science ®Google Scholar
• BertoPPassalacquaGCrimiNEconomic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) studyAnn Allergy Asthma Immunol20069761562117165269
   PubMed Web of Science ®Google Scholar
• CanonicaGWPoulsenPBVestenbaekUCost-effectiveness of Grazax for prevention of grass pollen-induced rhinoconjunctivitis in Southern EuropeRespir Med20071011885189417611095
   PubMed Web of Science ®Google Scholar
• NasserSVestenbaekUBeriot-MathiotACost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthmaAllergy2008631624162919032235
   PubMed Web of Science ®Google Scholar
• BufeAHenmarHGronagerPGrass allergen tablet immunotherapy in children induces IgG4 antibody and IgEblocking responses similar to those seen in adultsPoster presented at the XXVIII EAACI Congress of the European Academy of Allergy and Clinical ImmunologyWarszawa, PolandJune 6–10, 2009
   Google Scholar
• ALK-Abello LtdGrazax: Summary of product characteristicsHørsholm, DenmarkALK-Abello Ltd2007
   Google Scholar
• MosbechHOsterballeODoes the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitisAllergy1988435235293148282
   PubMed Web of Science ®Google Scholar
• British Medical Association and Royal Pharmaceutical Society of Great BritainBritish National Formulary 57London, UKBritish Medical Association and Royal Pharmaceutical Society of Great Britain2009
   Google Scholar
• CurtisLUnit Costs of Health and Social Care 2008Kent, UKPersonal Social Services Research Unit2008
   Google Scholar
• Department of HealthNHS Reference Costs 2007/08London, UKDepartment of Health2008
   Google Scholar
• DasguptaRGuestJFFactors affecting UK primary-care costs of managing patients with asthma over 5 yearsPharmacoeconomics20032135736912627989
   PubMed Web of Science ®Google Scholar
• NHS Quality Improvement ScotlandAsthma attack – targeting emergency asthma contacts in children2005 Available from: http://www.healthcareimprovementscotland.org/previous_resources/audit_report/asthma_emergency_contacts.aspx?theme=mobileAccessed October 3, 2013
   Google Scholar
• DrummondMFSculpherMJTorranceGWMethods for the Economic Evaluation of Health Care Programmes3rd edOxford, UKOxford University Press2005
   Google Scholar
• PetersenKDKronborgCGyrd-HansenDQuality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnairesAllergy20086328429118269674
   PubMed Web of Science ®Google Scholar
• National Prescribing CentreCommon questions about hay feverMeReC Bulletin2004141720
   Google Scholar
• European Federation of Allergy and Airway Diseases Patients AssociationResults of the patient voice allergy surveyImpact of allergic rhinitis in Europe [Summary Report]2005 Available from: http://www.efanet.org/2005/06/Accessed November 11, 2013
   Google Scholar
• HanmerJLawrenceWFAndersonJPReport of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scoresMed Decis Making20062639140016855127
   PubMed Web of Science ®Google Scholar
• SchermerTRThoonenBPvan den BoomGRandomized controlled economic evaluation of asthma self-management in primary health careAm J Respir Crit Care Med20021661062107212379549
   PubMed Web of Science ®Google Scholar
• HM TreasuryAppraisal and Evaluation in Central Government (The Green Book)London, UKHM Treasury2003 Available from: https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-governentAccessed October 3, 2013
   Google Scholar
• National Institute for Health and Clinical ExcellenceGuide to the Methods of Technology AppraisalLondon, UKNational Institute for Health and Clinical Excellence2008
   Google Scholar
• HankinCSCoxLLangDAllergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort studyAnn Allergy Asthma Immunol2010104798520143650
   PubMed Web of Science ®Google Scholar
• BruggenjurgenBReinholdTBrehlerRCost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthmaAnn Allergy Asthma Immunol200810131632418814456
   PubMed Web of Science ®Google Scholar
• KeidingHJorgensenKPA cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countriesCurr Med Res Opin2007231113112017519078
   PubMed Web of Science ®Google Scholar
• PokladnikovaJKrcmovaIVlcekJEconomic evaluation of sublingual vs subcutaneous allergen immunotherapyAnn Allergy Asthma Immunol200810048248918517082
   PubMed Web of Science ®Google Scholar
• BuxtonMJSullivanSDAnderssonLFCountry-specific cost-effectiveness of early intervention with budesonide in mild asthmaEur Respir J20042456857415459134
   PubMed Web of Science ®Google Scholar
• PaltielADFuhlbriggeALKitchBTCost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy modelJ Allergy Clin Immunol2001108394611447380
   PubMed Web of Science ®Google Scholar
• Rutten-van MolkenMPVan DoorslaerEKJansenMCCosts and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19951519759827697275
   PubMed Web of Science ®Google Scholar
• SullivanSDWeissKBLynnHThe cost-effectiveness of an inner-city asthma intervention for childrenJ Allergy Clin Immunol200211057658112373264
   PubMed Web of Science ®Google Scholar
• SmithAMRezvaniMBernsteinJAIs response to allergen immunotherapy a good phenotypic marker for differentiating between allergic rhinitis and mixed rhinitis?Allergy Asthma Proc201132495421262098
   PubMed Web of Science ®Google Scholar